Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.
Simmons and Torre clash over Belichick coverage ethics, sparking debate on boundaries of sports journalism.
Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.
Simmons and Torre clash over Belichick coverage ethics, sparking debate on boundaries of sports journalism.